Key clinical point: Colchicine reduced markers of inflammation in patients with metabolic syndrome.
Major finding: C-reactive protein dropped by 2.8 mg/L in the active group but increased slightly in the placebo group.
Study details: A randomized, placebo-controlled study comprising 40 patients
Disclosures: The study was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Institutes of Health. None of the authors reported any disclosures or conflicts of interest relating to this study.
Yanovski JA et al. Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13702.
This Week's Must Reads
Must Reads in Gout
FDA Approves Gloperba Oral Solution for Gout Flares, FirstWord Pharma news release; 2019 Feb 26
Sleep Quality, Sleep Disorders in People with Gout, Arthritis Res Ther; ePub 2019 Jan 25; Singh
Prevalence of Gout and Hyperuricemia in the US, Arthritis Rheumatol; ePub 2019 Jan 7; Chen-Xu, et al